Literature DB >> 2479409

Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).

T Ohtsuki1, Y Yawata, H Wada, T Sugihara, M Mori, M Namba.   

Abstract

Two human myeloma cell lines, KMS-12-PE and KMS-12-BM, were established from a 64-year-old woman with a non-producing type of multiple myeloma. The KMS-12-PE line originated from the pleural effusion and the KMS-12-BM from the bone marrow. These two lines showed the same chromosome marker, t(11:14)(q13:q32). However, their phenotypes of surface markers differed from each other. KMS-12-BM cells were positive to CD20, CD38 and PCA-1. showing the plasmacytoid (immature plasma cell) stage of B-cell differentiation, while KMS-12-PE cells were positive to CD38 and PCA-1, but not to CD20, indicating the terminal differentiated stage of B-cells. As seen in the pleural effusion of the patient. KMS-12-PE cells ectopically produced a salivary type of amylase, but KMS-12-BM cells did not. Interestingly, the chromosome abnormality of del(1)(p22----pter) near the region of 1p21, where the amylase gene was assigned, was noticed in as many as 76% of KMS-12-PE cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479409     DOI: 10.1111/j.1365-2141.1989.tb00252.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  A case of salivary-type amylase-producing multiple myeloma presenting as mediastinal plasmacytoma and myelomatous pleural effusion.

Authors:  Soon Jung Ok; In-Suk Kim; Eun Yup Lee; Jeong-Eun Kang; Sun-Min Lee; Moo-Kon Song
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

2.  Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis.

Authors:  Akiko Takata-Tomokuni; Ayako Ueki; Mieko Shiwa; Yumika Isozaki; Tamayo Hatayama; Hironobu Katsuyama; Fuminori Hyodoh; Wataru Fujimoto; Hiroaki Ueki; Masayasu Kusaka; Hisashi Arikuni; Takemi Otsuki
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

3.  Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.

Authors:  H Hata; H Matsuzaki; F Matsuno; T Sonoki; S Takemoto; N Kuribayashi; A Nagasaki; K Takatsuki
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

4.  Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors.

Authors:  Victor J Cee; Frank Chavez; Bradley Herberich; Brian A Lanman; Liping H Pettus; Anthony B Reed; Bin Wu; Ryan P Wurz; Kristin L Andrews; Jie Chen; Dean Hickman; Jimmy Laszlo; Matthew R Lee; Nadia Guerrero; Bethany K Mattson; Yen Nguyen; Christopher Mohr; Karen Rex; Christine E Sastri; Paul Wang; Qiong Wu; Tian Wu; Yang Xu; Yihong Zhou; Jeffrey T Winston; J Russell Lipford; Andrew S Tasker; Hui-Ling Wang
Journal:  ACS Med Chem Lett       Date:  2016-02-12       Impact factor: 4.345

5.  Amylase mRNA transcripts in normal tissues and neoplasms: the implication of different expressions of amylase isogenes.

Authors:  K Seyama; T Nukiwa; K Takahashi; H Takahashi; S Kira
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.

Authors:  Jyuri Watanuki; Kinta Hatakeyama; Takashi Sonoki; Hiro Tatetsu; Katsuhiko Yoshida; Soichiro Fujii; Minoru Mizutani; Toru Abo; Miwa Kurimoto; Hiroshi Matsuoka; Fumihiko Matsuno; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2009-07-29       Impact factor: 2.490

7.  Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.

Authors:  N Kuribayashi; H Hata; H Matsuzaki; M Yoshida; T Sonoki; A Nagasaki; T Kimura; N Harada; K Takatsuki
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

8.  Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Authors:  Yawara Kawano; Shiho Fujiwara; Naoko Wada; Mikiko Izaki; Hiromichi Yuki; Yutaka Okuno; Kenichi Iyama; Hiroshi Yamasaki; Akira Sakai; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2012-07-04       Impact factor: 5.650

9.  Pseudocyst or tumour? An amylase-producing leiomyosarcoma.

Authors:  T W Hennigan; M Collins; T C Naughton-Morgan; N A Theodorou
Journal:  J R Soc Med       Date:  1992-10       Impact factor: 18.000

10.  PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Authors:  S Fujiwara; Y Kawano; H Yuki; Y Okuno; K Nosaka; H Mitsuya; H Hata
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.